AR088579A1 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- AR088579A1 AR088579A1 ARP120104056A AR088579A1 AR 088579 A1 AR088579 A1 AR 088579A1 AR P120104056 A ARP120104056 A AR P120104056A AR 088579 A1 AR088579 A1 AR 088579A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- cdr
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Se proporcionan formulaciones que comprenden un anticuerpo anti-IL-1 3, incluyendo formulaciones farmacéuticas y métodos de uso de dichas formulaciones. Reivindicación 1: Una formulación que comprende un anticuerpo anti-IL13, en donde la concentración de anticuerpo en la formulación es de al menos 100 mg/mL y la viscosidad de la formulación es inferior a 15 centipoise (cP) a 25ºC. Reivindicación 2: La formulación de acuerdo con la reivindicación 1, en donde el anticuerpo anti-IL13 comprende tres CDR de cadena pesada, donde CDR-H1 tiene la secuencia de aminoácidos de SEQ ID Nº 1, CDR-H2 tiene la secuencia de aminoácidos de SEQ ID Nº 2 y CDR-H3 tiene la secuencia de aminoácidos de SEQ ID Nº 3 y tres CDR de cadena liviana, donde CDR-L1 tiene la secuencia de aminoácidos de SEQ ID Nº 4, CDR-L2 tiene la secuencia de aminoácidos de SEQ ID Nº 5 y CDR-L3 tiene la secuencia de aminoácidos de SEQ ID Nº 6. Reivindicación 11: La formulación de acuerdo con la reivindicación 1 que comprende tampón de acetato de histidina, pH 5,4 a 6,0, en donde la concentración de acetato de histidina en el tampón es de entre 5 mM y 40 mM. Reivindicación 12: La formulación de acuerdo con la reivindicación 11, que también comprende un poliol y un tensioactivo, en donde la concentración del poliol en la formulación es de entre 100 mM y 200 mM y la concentración del tensioactivo en la formulación es de entre el 0,01% y el 0,1%. Reivindicación 13: La formulación de acuerdo con la reivindicación 12, en donde el poliol es sacarosa y el tensioactivo es polisorbato 20.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553916P | 2011-10-31 | 2011-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088579A1 true AR088579A1 (es) | 2014-06-18 |
Family
ID=48192677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104056 AR088579A1 (es) | 2011-10-31 | 2012-10-30 | Formulaciones de anticuerpos |
| ARP210103246A AR124140A2 (es) | 2011-10-31 | 2021-11-24 | Formulaciones de anticuerpos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103246A AR124140A2 (es) | 2011-10-31 | 2021-11-24 | Formulaciones de anticuerpos |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10000562B2 (es) |
| EP (3) | EP3091029B1 (es) |
| JP (4) | JP6120452B2 (es) |
| KR (4) | KR102259829B1 (es) |
| CN (4) | CN116077644A (es) |
| AR (2) | AR088579A1 (es) |
| AU (3) | AU2012332767C1 (es) |
| BR (1) | BR112014008864B1 (es) |
| CA (2) | CA3078979C (es) |
| DK (1) | DK3091029T5 (es) |
| ES (1) | ES2936387T3 (es) |
| FI (1) | FI3091029T3 (es) |
| HK (1) | HK1201857A1 (es) |
| HR (1) | HRP20230153T1 (es) |
| HU (1) | HUE061728T2 (es) |
| IL (2) | IL232053B (es) |
| LT (1) | LT3091029T (es) |
| MX (2) | MX363226B (es) |
| MY (2) | MY197851A (es) |
| PL (1) | PL3091029T3 (es) |
| PT (1) | PT3091029T (es) |
| RS (1) | RS63948B1 (es) |
| RU (1) | RU2665810C2 (es) |
| SG (1) | SG11201401903PA (es) |
| SI (1) | SI3091029T1 (es) |
| WO (1) | WO2013066866A1 (es) |
| ZA (2) | ZA201401779B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| CA3101119C (en) | 2011-06-24 | 2023-07-04 | Kci Licensing, Inc. | Reduced-pressure dressings employing tissue-fixation elements |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| CN107880123A (zh) | 2011-10-28 | 2018-04-06 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
| KR102259829B1 (ko) * | 2011-10-31 | 2021-06-03 | 제넨테크, 인크. | 항체 제제 |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| NZ756750A (en) * | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015079977A1 (ja) * | 2013-11-26 | 2015-06-04 | シャープ株式会社 | 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| EP3590500B1 (en) | 2014-12-23 | 2025-06-25 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
| PL3448391T3 (pl) | 2016-04-27 | 2024-09-16 | AbbVie Manufacturing Management Unlimited Company | Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13 |
| MA46061A (fr) * | 2016-08-25 | 2019-07-03 | Boyce Thompson Institute For Plant Res | Traitement ascaroside de maladies auto-immunes et inflammatoires |
| RU2752785C2 (ru) * | 2016-09-23 | 2021-08-04 | Дженентек, Инк. | Применение антагонистов il-13 для лечения атопического дерматита |
| CN110167531B (zh) * | 2017-01-11 | 2025-06-03 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
| JP2019048091A (ja) * | 2018-10-23 | 2019-03-28 | ニプロ株式会社 | デクスメデトミジン注射液を充填したプレフィルドシリンジ |
| CN116106267A (zh) * | 2019-01-02 | 2023-05-12 | M & J科学有限责任公司 | 光散射检测器及用于其的方法 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| EP4065166A4 (en) * | 2019-11-26 | 2023-12-20 | Comera Life Sciences, Inc. | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS |
| JP2023547621A (ja) * | 2020-10-22 | 2023-11-13 | アラコス インコーポレイテッド | 抗ｓｉｇｌｅｃ－８抗体製剤 |
| TWI847170B (zh) | 2021-07-16 | 2024-07-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TWI859566B (zh) | 2021-08-13 | 2024-10-21 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| CN118076636A (zh) | 2021-09-15 | 2024-05-24 | 德米拉公司 | Il-13抑制剂用于治疗结节性痒疹 |
| KR20250039317A (ko) | 2022-05-05 | 2025-03-20 | 더미라, 인코포레이티드 | 아토피성 피부염의 치료를 위한 il-13 항체 |
| CR20250009A (es) | 2022-06-17 | 2025-05-07 | Apogee Biologics Inc | Anticuerpos que se unen a interleuquina 13 y métodos de uso |
| CN120826237A (zh) | 2023-03-08 | 2025-10-21 | 德米拉公司 | Il-13抗体用于治疗特应性皮炎 |
| WO2025076280A1 (en) | 2023-10-05 | 2025-04-10 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| WO2025128984A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps |
| WO2025128990A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of perennial allergic rhinitis |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025137410A1 (en) * | 2023-12-20 | 2025-06-26 | Apogee Therapeutics, Inc. | Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine |
| WO2025137523A2 (en) * | 2023-12-20 | 2025-06-26 | Apogee Therapeutics, Inc. | Pharmaceutical formulations of antibodies that bind interleukin 13 |
| WO2025155802A1 (en) * | 2024-01-19 | 2025-07-24 | Allakos Inc. | Anti-siglec-6 antibody formulations |
| WO2025184453A1 (en) | 2024-03-01 | 2025-09-04 | Dermira, Inc. | Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| EP1013270A3 (en) | 1992-12-02 | 2001-03-28 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| WO1996007399A1 (en) | 1994-09-09 | 1996-03-14 | Takeda Chemical Industries, Ltd. | Sustained release preparation containing metal salt of a peptide |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP0831787B1 (en) | 1995-06-07 | 2001-08-22 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| JP4533626B2 (ja) * | 2001-11-07 | 2010-09-01 | サイトス バイオテクノロジー アーゲー | アレルギー性好酸球性疾患を治療するための抗原アレイ |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| CN100563712C (zh) * | 2003-02-28 | 2009-12-02 | 阿雷斯贸易股份有限公司 | 肿瘤坏死因子结合蛋白的液体制剂 |
| DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| ES2775204T3 (es) | 2003-12-23 | 2020-07-24 | Genentech Inc | Nuevos anticuerpos anti IL13 y usos de los mismos |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007036745A2 (en) | 2005-09-30 | 2007-04-05 | Medimmune Limited | Interleukin-13 antibody composition |
| JP5006330B2 (ja) * | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| CL2008000058A1 (es) | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
| CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| CN105363037B (zh) * | 2008-12-03 | 2019-02-05 | 安斯泰来德国有限公司 | 苯达莫司汀的口服剂型 |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| CA2792125C (en) * | 2010-03-22 | 2019-02-12 | Genentech, Inc. | Compositions and methods useful for stabilizing protein-containing formulations |
| WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| KR102259829B1 (ko) * | 2011-10-31 | 2021-06-03 | 제넨테크, 인크. | 항체 제제 |
-
2012
- 2012-10-30 KR KR1020207015572A patent/KR102259829B1/ko active Active
- 2012-10-30 HU HUE16169916A patent/HUE061728T2/hu unknown
- 2012-10-30 FI FIEP16169916.0T patent/FI3091029T3/fi active
- 2012-10-30 PL PL16169916.0T patent/PL3091029T3/pl unknown
- 2012-10-30 RU RU2014116070A patent/RU2665810C2/ru active
- 2012-10-30 DK DK16169916.0T patent/DK3091029T5/da active
- 2012-10-30 HR HRP20230153TT patent/HRP20230153T1/hr unknown
- 2012-10-30 JP JP2014539136A patent/JP6120452B2/ja active Active
- 2012-10-30 CN CN202210876554.2A patent/CN116077644A/zh active Pending
- 2012-10-30 CN CN201810964732.0A patent/CN108704132A/zh active Pending
- 2012-10-30 CA CA3078979A patent/CA3078979C/en active Active
- 2012-10-30 MX MX2014004992A patent/MX363226B/es unknown
- 2012-10-30 RS RS20230095A patent/RS63948B1/sr unknown
- 2012-10-30 CA CA2849210A patent/CA2849210C/en active Active
- 2012-10-30 AR ARP120104056 patent/AR088579A1/es not_active Application Discontinuation
- 2012-10-30 MY MYPI2018001912A patent/MY197851A/en unknown
- 2012-10-30 EP EP16169916.0A patent/EP3091029B1/en active Active
- 2012-10-30 LT LTEP16169916.0T patent/LT3091029T/lt unknown
- 2012-10-30 AU AU2012332767A patent/AU2012332767C1/en active Active
- 2012-10-30 SG SG11201401903PA patent/SG11201401903PA/en unknown
- 2012-10-30 KR KR1020197018310A patent/KR20190077127A/ko not_active Ceased
- 2012-10-30 MY MYPI2014001225A patent/MY187874A/en unknown
- 2012-10-30 CN CN201810964731.6A patent/CN109078182B/zh active Active
- 2012-10-30 EP EP12846324.7A patent/EP2773662A4/en not_active Withdrawn
- 2012-10-30 EP EP22208284.4A patent/EP4218937A3/en active Pending
- 2012-10-30 PT PT161699160T patent/PT3091029T/pt unknown
- 2012-10-30 HK HK15102358.5A patent/HK1201857A1/xx unknown
- 2012-10-30 ES ES16169916T patent/ES2936387T3/es active Active
- 2012-10-30 WO PCT/US2012/062572 patent/WO2013066866A1/en not_active Ceased
- 2012-10-30 KR KR20147011246A patent/KR20140084078A/ko not_active Ceased
- 2012-10-30 CN CN201280053245.XA patent/CN104039826A/zh active Pending
- 2012-10-30 KR KR1020177022308A patent/KR101994809B1/ko active Active
- 2012-10-30 SI SI201232018T patent/SI3091029T1/sl unknown
- 2012-10-31 BR BR112014008864-0A patent/BR112014008864B1/pt active IP Right Grant
-
2014
- 2014-03-11 ZA ZA2014/01779A patent/ZA201401779B/en unknown
- 2014-04-10 IL IL232053A patent/IL232053B/en active IP Right Grant
- 2014-04-23 US US14/259,882 patent/US10000562B2/en active Active
- 2014-04-24 MX MX2019002979A patent/MX2019002979A/es unknown
-
2016
- 2016-06-08 JP JP2016114267A patent/JP6272950B2/ja active Active
- 2016-08-05 AU AU2016210757A patent/AU2016210757A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017202159A patent/JP2018048166A/ja not_active Withdrawn
-
2018
- 2018-06-07 US US16/002,932 patent/US10947307B2/en active Active
- 2018-09-19 AU AU2018232943A patent/AU2018232943B2/en active Active
-
2019
- 2019-03-11 ZA ZA2019/01490A patent/ZA201901490B/en unknown
- 2019-06-25 JP JP2019116979A patent/JP6921148B2/ja active Active
-
2020
- 2020-07-22 IL IL276234A patent/IL276234B/en unknown
-
2021
- 2021-02-04 US US17/167,754 patent/US12492247B2/en active Active
- 2021-11-24 AR ARP210103246A patent/AR124140A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088579A1 (es) | Formulaciones de anticuerpos | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| ES2523740T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
| PE20040519A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| AR092216A1 (es) | Formulaciones estables de anticuerpos contra tslp | |
| AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| CO6480962A2 (es) | Anticuerpos anti-vegf y sus usos | |
| FI4339615T3 (sv) | Anti-PD-1-antikroppar för användande vid behandling av cancer | |
| JP2016531914A5 (es) | ||
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
| PE20240819A1 (es) | Anticuerpos anti-hla-g y uso de estos | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| PE20130214A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| PE20212324A1 (es) | Anticuerpos que reconocen tau | |
| RU2010145177A (ru) | Лекарственное средство для лечения рака печени | |
| PE20121645A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |